The Food and Drug Administration has approved a treatment for bone-marrow cancer based on research conducted in Israel. The velcade injection, developed by Millennium Pharmaceuticals of Cambridge, Mass., following 30 years of research by professor Avraham Hershko of Israel’s Technion, is the “first in a new class of anti-cancer agents known as proteasome inhibitors.”
Keep Jewish Stories in Focus.
JTA has documented Jewish history in real-time for over a century. Keep our journalism strong by joining us in supporting independent, award-winning reporting.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
